REDONDO BEACH, CA--(Marketwired - Aug 11, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces the release of an article covering Innovus Pharmaceuticals' (OTCQB: INNV) recent quarterly financial results and the numerous upcoming catalysts for the company's stock.

Innovus announced record revenue of $1 million during the second quarter, driven by its recent acquisition of Beyond Human and organic growth across its core product lines. For the full year, management expects to reach the 'higher end' of its $3-5 million in projected revenue without factoring in any potential gains from FlutiCare™ -- a nasal allergy spray that's currently under review by the FDA.

"We have exceeded our commercial expectations, and with the projected launch of Sensum+®, RecalMax™, and Xyralid® in the second half of 2016, we believe that revenues will continue to increase through the balance of 2016 and into 2017 and exceed our projections," said Innovus Pharmaceuticals President & CEO Dr. Bassam Damaj.

To read the article on, please click the link:

For more information, visit the company's website at or download our free Company Analysis.


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information:

Paul Archie
406 862 2242